Rhythm Pharmaceuticals (NASDAQ:RYTM) posted its earnings results on Monday. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.14, Bloomberg Earnings reports.

Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) opened at $29.15 on Wednesday. Rhythm Pharmaceuticals has a 52 week low of $21.38 and a 52 week high of $33.81.

Several research firms have issued reports on RYTM. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 target price on shares of Rhythm Pharmaceuticals in a research note on Monday, February 26th. BidaskClub lowered Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, February 22nd. Finally, Cowen reiterated a “buy” rating and issued a $40.00 target price on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $31.25.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/03/14/rhythm-pharmaceuticals-rytm-issues-quarterly-earnings-results.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.